Crescent Biopharma financials
$14.76+1.58%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 | FY15 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.8M | $102.3M | $7.3M | $20.9M | — | $6.0K | $1.0M | $399.0K | $1.8M |
| Gross profit | $10.8M | $97.5M | -$42.0K | $11.8M | — | $6.0K | $1.0M | $399.0K | $1.8M |
| Gross margin | 100.0% | 95.3% | −0.6% | 56.3% | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$152.6M | $9.2M | -$87.9M | -$57.4M | -$57.3M | -$33.8M | -$21.8M | -$20.4M | -$13.8M |
| Net income | -$133.4M | $2.3M | -$87.9M | -$56.2M | -$55.2M | -$30.1M | -$25.5M | -$16.9M | -$14.8M |
| Net margin | −1230.6% | 2.3% | −1198.3% | −268.5% | — | −500916.7% | −2506.1% | −4246.9% | −843.5% |
| Diluted EPS | $-12.81 | $0.03 | $-43.05 | $-43.95 | $-69.00 | $-40.20 | $-111.75 | $-326.25 | $-749.85 |
| EBITDA | -$152.5M | $10.3M | -$87.6M | -$57.2M | -$57.1M | -$33.7M | -$21.6M | -$20.0M | -$13.3M |
| Operating cash flow | -$71.5M | $10.7M | -$83.8M | -$55.0M | -$43.6M | -$28.6M | -$19.9M | -$18.5M | -$19.1M |
| Free cash flow | -$72.5M | $5.7M | -$84.6M | — | — | -$28.9M | -$20.0M | -$18.9M | -$19.4M |
| Diluted shares | 10.4M | 75.7M | 2.0M | 1.3M | 0.8M | 0.7M | 0.2M | 0.1M | 0.0M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $213.2M | $25.2M | $44.3M | $30.4M | $15.4M | $31.2M |
| Short-term investments | $0.00 | $0.00 | $2.5M | $49.0M | $61.5M | $88.9M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $240.3M | $84.8M | $55.7M | $94.8M | $98.6M | $124.9M |
| Total liabilities | $37.3M | $12.5M | $14.6M | $18.8M | $30.2M | $5.0M |
| Shareholders' equity | $203.0M | $72.2M | $41.1M | $76.1M | $68.3M | $119.9M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology